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Abstract
Background: Acute promyelocytic leukemia is characterized by a typical reciprocal translocation t(15;17)(q22;q21).
Additional chromosomal abnormalities are reported in only 23–43 % of cases of acute promyelocytic leukemia.
Case presentation: Here we report the case of a 46-year-old Syrian Alawis woman with acute promyelocytic
leukemia with the typical t(15;17) translocation, but with a second clone presenting a t(1;2)(q42~43;q11.2~12)
translocation as an additional abnormality. To the best of our knowledge, an association between these
chromosomal abnormalities has not previously been described in the literature. Our patient started treatment
with all-trans retinoic acid 10 days after diagnosis but died the same day of treatment initiation due to hemolysis,
intracranial hemorrhage, thrombocytopenia, and disseminated intravascular coagulation.
Conclusion: The here reported combination of aberrations in a case of acute promyelocytic leukemia seems to
indicate an adverse prognosis, and possibly shows that all-trans retinoic acid treatment may be contraindicated in
such cases.
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Background
Acute promyelocytic leukemia (APL) accounts for 5–10 %
of acute myeloid leukemia (AML) and is a very distinct
subtype (subtype M3) with regard to clinical, morphologic,
and prognostic features. The median age of patients with
APL is 30–40 years [1]. APL is characterized by the recip-
rocal translocation t(15;17)(q22;q21) in ~90 % of cases [1].
At the molecular level, as a result of the t(15;17) transloca-
tion, the gene for retinoic acid receptor alpha (RARA) on
17q21 fuses with a transcription factor gene (promyelocy-
tic leukemia or PML) on 15q22, giving rise to a PML/
RARA gene fusion product [2]. This PML/RARA fusion
gene transcript is known to play a pivotal role in the
pathogenesis of APL and the sensitivity to all-trans retin-
oic acid (ATRA) [3]. Approximately 70–80 % of patients
with newly diagnosed APL carrying PML/RARA achieve
long-term remission; however, some patients still have a
poor outcome [3].
Balanced chromosomal rearrangements are detected
in 25–30 % of adults with de novo AML [3, 4] and have
attracted a great deal of attention because of specific
translocations and inversions associated with the progno-
sis for these patients. Additional chromosomal aberrations
(ACAs) associated with t(15;17) are reported in 23–43 %
of APL cases [5–7]. The clinical impact of these ACAs has
not yet been clearly elucidated.
Here we report the case of a patient exhibiting an im-
munophenotype consistent with APL, a t(15;17)(q22;q21)
translocation, and a t(1;2)(q42~43;q11.2~12) translocation,
with the clinical characteristics of hyperleukocytosis (HL),
thrombocytopenia, and disseminated intravascular coagu-
lation (DIC). Our patient did not benefit from ATRA treat-
ment and died due to hemolysis, intracranial hemorrhage,
thrombocytopenia, and DIC.
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Case presentation
A 46-year-old Syrian Alawis woman without a significant
personal or familial medical history presented with a 1-
month history of multiple sclerosis, fatigue, loss of weight,
fever, and an elevated white blood cell (WBC) count. An
initial evaluation revealed that she had anemia (8.5 g/dL),
leukocytosis (total leukocyte count 134 × 109/L), and
thrombocytopenia (23 × 109/L). She was pale and did not
have lymphadenopathy.
Our patient was transferred to the hospital because
she was unconscious and making noise during breathing.
Novel hematological parameters included anemia (8.2 g/
dL), thrombocytopenia (29 × 109/L), leukocytosis (229 ×
109/L), a plasma concentration of fibrinogen of 37 mg/
dL (normal value, 200–400 mg/dL), and a prothrombin
time of 18 s (normal value, 10.0–13.0 s). She received
several blood transfusions. Our patient stayed in the
hospital for 1 week. On the same day of treatment initi-
ation with ATRA (45 mg/m2 daily dose), our patient died,
10 days after her diagnosis. An autopsy revealed death was
due to hemolysis, intracranial hemorrhage, thrombo-
cytopenia, and DIC. Cytogenetic and immunophenotyping
analyses were also carried out. Our patient was diagnosed
with APL according to the World Health Organization
(WHO) classification and was considered high risk based
on her WBC. Her brother gave consent for a scientific
evaluation of her case and the study was approved by the
ethical committee of the Atomic Energy Commission,
Damascus, Syria.
A chromosome analysis using GTG-banding was
performed according to standard procedures [8] before
treatment with ATRA and revealed a karyotype of
46,XX,t(15;17)[8]/46,XX,t(1;2),t(15;17)[11]/46,XX [1]
(Fig. 1). Further studies were performed based on mole-
cular cytogenetics (Figs. 2 and 3). Dual-color fluorescence
in situ hybridization (D-FISH) using a specific probe for
PML and RARA (Abbott Molecular/Vysis, Des Plaines, IL,
USA) revealed the presence of the PML/RARA fusion gene
on der(15) (Fig. 2). Chromosomes 1, 2, 15, and 17 were
studied with Whole Chromosome Paint (WCP) probes
(MetaSystems, Altlussheim, Germany) [8], which did not
provide any information on the cryptic translocations (data
not shown). Array-proven high-resolution multicolor band-
ing (aMCB) [9] was performed using probes corresponding
to chromosomes 1 and 2, which were identified by GTG-
banding as being involved (Fig. 3). The following final
karyotype was determined prior to chemotherapy treatment
using a fluorescence microscope (AxioImager.Z1 mot, Carl
Zeiss Ltd., Welwyn Garden City, UK) equipped with appro-
priate filter sets to discriminate between a maximum of five
fluorochromes plus the counterstain DAPI (4',6- diamino-
2-phenylindole). Image capture and processing were




Image capture and processing were performed using
an ISIS imaging system (MetaSystems).
Fig. 1 GTG-banding revealed the following karyotype: 46,XX,t(1;2)(q42~43;q11.2~12),t(15;17)(q22;q21). All derivative chromosomes are marked and
highlighted by arrow heads
Wafa et al. Journal of Medical Case Reports  (2016) 10:203 Page 2 of 5
Immunophenotyping was performed using a general
panel of fluorescent antibodies against the following
antigens typical for different cell lineages and cell types:
CD1a, CD2, CD3, CD4, CD5, CD8, CD10, CD11b,
CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22,
CD23, CD32, CD33, CD34, CD38, CD41a, CD45, CD56,
CD57, CD64, CD103, CD117, CD123, CD138, CD209,
CD235a, and CD243. In addition, antibodies to kappa
and lambda light chains, IgD, sIgM, and HLADr were
tested. All antibodies were purchased from BD Biosci-
ences, San Jose, CA, USA. Samples were analyzed on a
BD FACSCalibur™ flow cytometer. Autofluorescence,
viability, and isotype controls were included. Flow cyto-
metric data acquisition and analysis were conducted by
BD Cellquest™ Pro software. Flow cytometric analysis of
a peripheral blood specimen from our patient character-
ized this case as APL according to WHO classifications.
The abnormal cell population (97 % of tested cells) was
positive for MPO++, CD45+dim, CD34−, HLADr−, CD33+,
CD13+, CD16−, CD64+, CD15+dim, and CD14−.
Discussion
According to the literature, APL is characterized by the
t(15;17) translocation that generates the PML/RARA fu-
sion gene and induces sensitivity to ATRA [3]. To date,
1402 APL cases with t(15;17) have been reported in the
Mitelman Database [10]. Only three cases demonstrated
involvement of a t(1;2) translocation in addition to
t(15;17): the first case was a t(1;2)(p22;q31), the second a
t(1;2)(q43;p21), and the third a t(1;2;3)(p36;q21;p21)
[10]. To the best of our knowledge, this is the first report
of a case of APL with t(15;17)(q22;q21) associated with
t(1;2)(q42~43;q11.2~12).
In addition, chromosomal band 1q42 is reported in
two cases, 1q43 in one, and 2q12 in one case in the
Mitelman Database [10]. Chromosomal band 2q11.2 has
not yet been reported in APL [10].
Additional chromosome aberrations to t(15;17) have been
observed in 23–43 % of APL cases, but their prognostic
significance remains controversial [5–7]. The majority of
evidence supports the concept that patients with additional
chromosomal abnormalities have the same favorable progno-
sis as patients with t(15;17) alone [5, 7]; however, a previous
study has found that chromosomal abnormalities in addition
to t(15;17) are associated with a poorer prognosis [6].
In contrast, another study showed that additional
chromosomal abnormalities are associated with a slightly
better prognosis (no effect on overall survival) [11]. More-
over, some reports found that ACAs had no effect on
prognosis [7, 12]. However, some newly diagnosed pa-
tients and patients with relapsing disease with identical
cytogenetic changes showed an adverse outcome [6, 13].
The most frequent secondary aberration to t(15;17) is
trisomy 8 (+8). Other additional chromosome changes in-
clude del(9q); del(7q); abnormalities of chromosome 1, 3,
and 6; trisomy 21; and isochromosome of the long arm of
the derivative chromosome 17 originating from the trans-
location t(15;17) [ider(17)(q10)t(15;17) or ider(17q)] [5].
Zaccaria et al. [14] reported that a patient with APL asso-
ciated with a PML/RARA fusion gene on chromosome 17
responded poorly to ATRA treatment. However, complete
remission rates are usually 87–94 % using ATRA alone at a
classical dosage of 45 mg/m2/day for 4–6 weeks [15].
Thus, it is not clear whether the novel cytogenetic
findings in the present case relate to a slower than usual
response to ATRA induction therapy. Furthermore, the
presence of specific ACAs associated with translocation
t(15;17) might be indicative of a poor outcome.
Clinically, APL has a high frequency of hemorrhage
due to DIC, which contributes to the high mortality
rates of this disease [16, 17]. However, DIC is a coagulopa-
thy induced by the formation of small clots consuming
coagulation proteins and platelets, resulting in disruption
of normal coagulation and severe bleeding tendency [18].
Acute DIC is characterized by a decrease in platelet count
and fibrinogen, an elevation of D-dimers, and prolonga-
tion of prothrombin time and activated partial thrombo-
plastin time; it occurs in 30–40 % of HL-AML [19].
Five to twenty percent of patients with untreated AML
present with HL, that is, WBC counts of >100,000 cells/
mL [20]. HL may cause three main complications: (i)
DIC, (ii) tumor lysis syndrome, and (iii) leukostasis.
These may cause life-threatening complications in pa-
tients with AML [19]. Early mortality in this patient
group is higher than in AML without HL and ranges
Fig. 2 Fluorescence in situ hybridization using an LSI PML/RARA
dual-color translocation probe for RARA (green) and PML (red)
confirmed the presence of the PML/RARA fusion gene on der(15).
# chromosome, der derivative chromosome
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from 6 % versus 1 % after 1 week and 13 % versus 7 %
after 30 days [19]. The main causes of death are bleeding,
thromboembolic events, and neurologic and pulmonary
complications [21]. HL is a negative prognostic factor, as
indicated by significantly shorter overall survival [22].
Approximately 44–50 % of patients with AML with a
WBC count >100,000 cells/mL have a high probability
of leukostasis. Organs most frequently affected are lung,
brain, and kidneys [20]. As well as the tissue damage
caused by stasis and leukocyte infiltration, hemorrhage
and thromboembolic events are frequent and relevant
complications of leukostasis [18].
Conclusions
Here, we have described a case of APL characterized by
HL, thrombocytopenia, and DIC associated with transloca-
tion t(15;17) and translocation t(1;2)(q42~43;q11.2~12).
Because translocation t(15;17) is normally successfully
treatable with ATRA even when ACAs are present, the
adverse outcome in the present patient was surprising.
Thus, the translocation t(1;2)(q42~43;q11.2~12) may be a
new predictor for a more severe course of APL.
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